The Feasibility of [F]EF5-PET/CT to Image Hypoxia in Ovarian Tumors: a Clinical Study

Overview

Journal EJNMMI Res

Date 2020 Sep 10

PMID 32910291

Citations 2

Authors

Maren Laasik

Johanna Hynninen

Sarita Forsback

Tommi Noponen

Marko Seppanen

Sakari Hietanen

Affiliations

Soon will be listed here.

Abstract

Rationale: Evaluation of the feasibility of [F]EF5-PET/CT scan in identifying hypoxic lesions in ovarian tumors in prospective clinical setting.

Methods: Fifteen patients with a suspected malignant ovarian tumor were scanned with [F]EF5 and [F]FDG-PET/CT preoperatively. The distribution of [F]EF5-uptake, total intraabdominal metabolic tumor volume (TMTV), and hypoxic subvolume (HSV) were assessed.

Results: [F]EF5-PET/CT suggested hypoxia in 47% (7/15) patients. The median HSV was 87 cm (31% of TMTV). The [F]EF5-uptake was detected in primary tumors and in four patients also in intra-abdominal metastases. The [F]EF5-uptake in cancer tissue was low compared to physiological excretory pathways, complicating the interpretation of PET/CT images.

Conclusions: [F]EF5-PET/CT is not feasible in ovarian cancer imaging in clinical setting due to physiological intra-abdominal [F]EF5-accumulation. However, it may be useful when used complementarily to FDG-PET/CT.

Citing Articles

Advances in PET and MRI imaging of tumor hypoxia.

Gouel P, Decazes P, Vera P, Gardin I, Thureau S, Bohn P Front Med (Lausanne). 2023; 10:1055062.

PMID: 36844199 PMC: 9947663. DOI: 10.3389/fmed.2023.1055062.

Construction and Verification of a Hypoxia-Related 4-lncRNA Model for Prediction of Breast Cancer.

Zhao Y, Liu L, Zhao J, Du X, Yu Q, Wu J Int J Gen Med. 2021; 14:4605-4617.

PMID: 34429643 PMC: 8380141. DOI: 10.2147/IJGM.S322007.

References

Vaupel P, Mayer A . Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26(2):225-39. DOI: 10.1007/s10555-007-9055-1. View

Kinoshita T, Fujii H, Hayashi Y, Kamiyama I, Ohtsuka T, Asamura H . Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer. Lung Cancer. 2015; 91:56-66. DOI: 10.1016/j.lungcan.2015.11.020. View

Cormio G, Rossi C, Cazzolla A, Resta L, Loverro G, Greco P . Distant metastases in ovarian carcinoma. Int J Gynecol Cancer. 2003; 13(2):125-9. DOI: 10.1046/j.1525-1438.2003.13054.x. View

Bristow R, Tomacruz R, Armstrong D, Trimble E, Montz F . Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002; 20(5):1248-59. DOI: 10.1200/JCO.2002.20.5.1248. View

Yapp D, Woo J, Kartono A, Sy J, Oliver T, Skov K . Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography. BJU Int. 2007; 99(5):1154-60. DOI: 10.1111/j.1464-410X.2007.06761.x. View

Holmes D . Ovarian cancer: beyond resistance. Nature. 2015; 527(7579):S217. DOI: 10.1038/527S217a. View

Lin L, Silvoniemi A, Stubbs J, Rengan R, Suilamo S, Solin O . Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patients. Cancer Biother Radiopharm. 2012; 27(7):412-9. DOI: 10.1089/cbr.2011.1130. View

Qian Y, von Eyben R, Liu Y, Chin F, Miao Z, Apte S . F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018; 102(4):1183-1192. DOI: 10.1016/j.ijrobp.2018.03.045. View

Komar G, Seppanen M, Eskola O, Lindholm P, Gronroos T, Forsback S . 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med. 2008; 49(12):1944-51. DOI: 10.2967/jnumed.108.053785. View

10.

Rankin E, Giaccia A . Hypoxic control of metastasis. Science. 2016; 352(6282):175-80. PMC: 4898055. DOI: 10.1126/science.aaf4405. View

11.

Shen W, Li H, Liu L, Cheng J . Expression levels of PTEN, HIF-1α, and VEGF as prognostic factors in ovarian cancer. Eur Rev Med Pharmacol Sci. 2017; 21(11):2596-2603. View

12.

Chapman J, Franko A, Sharplin J . A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer. 1981; 43(4):546-50. PMC: 2010627. DOI: 10.1038/bjc.1981.79. View

13.

Eskola O, Gronroos T, Forsback S, Tuomela J, Komar G, Bergman J . Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [(18)F]EF5. Mol Imaging Biol. 2011; 14(2):205-12. DOI: 10.1007/s11307-011-0484-4. View

14.

Natarajan S, Foreman K, Soriano M, Rossen N, Shehade H, Fregoso D . Collagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer Metastasis. Cancer Res. 2019; 79(9):2271-2284. PMC: 6822898. DOI: 10.1158/0008-5472.CAN-18-2616. View

15.

Silvoniemi A, Suilamo S, Laitinen T, Forsback S, Loyttyniemi E, Vaittinen S . Repeatability of tumour hypoxia imaging using [F]EF5 PET/CT in head and neck cancer. Eur J Nucl Med Mol Imaging. 2017; 45(2):161-169. PMC: 5745570. DOI: 10.1007/s00259-017-3857-3. View

16.

Rasey J, Grunbaum Z, Magee S, Nelson N, Olive P, Durand R . Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res. 1987; 111(2):292-304. View

17.

Busch T, Hahn S, Wileyto E, Koch C, Fraker D, Zhang P . Hypoxia and Photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients. Clin Cancer Res. 2004; 10(14):4630-8. DOI: 10.1158/1078-0432.CCR-04-0359. View

18.

Gaertner F, Souvatzoglou M, Brix G, Beer A . Imaging of hypoxia using PET and MRI. Curr Pharm Biotechnol. 2012; 13(4):552-70. DOI: 10.2174/138920112799436267. View

19.

Koch C, Scheuermann J, Divgi C, Judy K, Kachur A, Freifelder R . Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging. 2010; 37(11):2048-59. PMC: 2948639. DOI: 10.1007/s00259-010-1517-y. View

20.

Komar G, Lehtio K, Seppanen M, Eskola O, Levola H, Lindholm P . Prognostic value of tumour blood flow, [¹⁸F]EF5 and [¹⁸F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy. Eur J Nucl Med Mol Imaging. 2014; 41(11):2042-50. DOI: 10.1007/s00259-014-2818-3. View